ProKidney Corp. (NASDAQ:PROK) Receives Average Rating of “Hold” from Brokerages

ProKidney Corp. (NASDAQ:PROK) has been assigned a consensus rating of “Hold” from the seven brokerages that are covering the company, Marketbeat Ratings reports. Two analysts have rated the stock with a sell recommendation, one has assigned a hold recommendation and four have assigned a buy recommendation to the company. The average 12 month price target among analysts that have issued ratings on the stock in the last year is $7.40.

PROK has been the topic of a number of research analyst reports. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of ProKidney in a research report on Thursday, January 22nd. HC Wainwright started coverage on ProKidney in a research note on Tuesday, December 16th. They set a “buy” rating and a $12.00 target price for the company.

Insider Activity at ProKidney

In related news, Director Brian Jg Pereira sold 502,136 shares of the firm’s stock in a transaction on Thursday, November 13th. The shares were sold at an average price of $2.37, for a total transaction of $1,190,062.32. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. 41.49% of the stock is currently owned by insiders.

Hedge Funds Weigh In On ProKidney

A number of large investors have recently added to or reduced their stakes in PROK. FNY Investment Advisers LLC lifted its holdings in shares of ProKidney by 590,620.0% in the fourth quarter. FNY Investment Advisers LLC now owns 59,052 shares of the company’s stock valued at $132,000 after purchasing an additional 59,062 shares in the last quarter. Hennion & Walsh Asset Management Inc. grew its holdings in shares of ProKidney by 63.5% during the fourth quarter. Hennion & Walsh Asset Management Inc. now owns 1,503,886 shares of the company’s stock worth $3,369,000 after buying an additional 583,983 shares in the last quarter. Millennium Management LLC acquired a new stake in ProKidney in the 3rd quarter valued at approximately $4,734,000. Virtu Financial LLC bought a new stake in ProKidney in the 3rd quarter valued at approximately $203,000. Finally, Two Sigma Investments LP boosted its position in ProKidney by 40.4% during the 3rd quarter. Two Sigma Investments LP now owns 99,282 shares of the company’s stock worth $240,000 after acquiring an additional 28,583 shares during the last quarter. Institutional investors own 51.59% of the company’s stock.

ProKidney Stock Performance

Shares of NASDAQ PROK opened at $1.98 on Friday. The firm has a 50 day moving average price of $2.27 and a 200 day moving average price of $2.57. The stock has a market cap of $595.64 million, a P/E ratio of -3.60 and a beta of 1.79. ProKidney has a 52-week low of $0.46 and a 52-week high of $7.13.

ProKidney (NASDAQ:PROK) last announced its quarterly earnings results on Monday, November 10th. The company reported ($0.12) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.12). The firm had revenue of $0.22 million during the quarter, compared to analyst estimates of $0.04 million. Analysts predict that ProKidney will post -0.57 earnings per share for the current fiscal year.

About ProKidney

ProKidney, Inc (NASDAQ: PROK) is a clinical-stage biotechnology company focused on developing cell-based therapies for kidney diseases. The company’s research and development activities center on harnessing human-derived proximal tubule cells to address conditions such as acute kidney injury (AKI) and chronic kidney disease (CKD). By targeting the underlying cellular mechanisms of renal injury and dysfunction, ProKidney aims to offer novel regenerative medicine approaches that go beyond current supportive care options.

ProKidney’s lead programs utilize proprietary methods for isolating and expanding renal epithelial cells to create injectable therapeutic products.